首页> 外国专利> Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland

Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland

机译:评估乳腺非侵袭性原位癌发展风险的方法

摘要

The invention refers to medicine, particularly oncology and can be used for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland for determining the treatment.Summary of the invention includes carrying out of clinical, ultrasound and mammographic investigations, carrying out of computer tomography. If clininally are not revealed objective or subjective signs or it is determined presence of serous discharge from the mammary gland duct, at the ultrasound examination are revealed diffuse changes in the glandular tissue, at the mammographic examination are determined up to 5 microcalcificates to 1 cm2, according to Le Gal I-st or II-nd type, according to the Classification of the American College of Radiology (ACR) 1, 2 or 3 and at the computer tomography without pathology and absence of suspicious regional lymph nodes for presence of metastases, it is appreciated a minor risk of development of the noninvasive carcinoma in situ. If clinically there are present inflammation signs or induration with serous or serous-bloody discharge from the mammary gland duct, at the ultrasound examination it is revealed the localized fibroadenomatosis, suspicion of microcalcificates presence, at the mammographic examination there are determined up to 10 microcalcificates to 1 cm2, according to Le Gal III-rd type, according to ACR 4 and at the computer tomography is determined induration, up to 10 microcalcificates to 1 cm2, intraductal papilloma and absence of suspicious regional lymph nodes for presence of matastases, it is appreciated a medium risk of development of the noninvasive carcinoma in situ, and if clinically is determined induration or tumoral formation with bloody discharge, at the ultrasound examination it is revealed the localized fibroadenomatosis or a formation with microcalcificates, at the mammographic examination there are revealed more than 10 microcalcificates to 1 cm2, according to Le Gal IV -V type, according to ACR 5 and at the computer tomography is determined tumor with reduced density or localized fibroadenomatosis, multiple intraductal papillomae, more than 10 microcalcificates to 1 cm2 and absence of suspicious regional lymph nodes for presence of metastases, it is appreciated a major risk of development of the noninvasive carcinoma in situ.
机译:本发明涉及医学,特别是肿瘤学,并且可用于评估乳腺原位非侵袭性癌发展的风险以确定治疗方法。本发明的概述包括进行临床,超声和乳房X线检查,进行断层扫描技术。如果未在临床上发现客观或主观症状,或确定存在乳腺导管浆液性分泌物,则在超声检查中发现腺组织中存在弥漫性变化,在乳房X线检查中确定最多5个微钙化至1 cm2,根据Le Gal I-st或II-nd类型,根据美国放射学院(ACR)1、2或3的分类,并且在计算机X线断层摄影术中,无病理学且没有可疑的局部淋巴结转移人们认识到非侵入性原位癌发展的风险很小。如果临床上从乳腺管出现炎症迹象或有浆液性或浆液性血肿硬结,则在超声检查中可发现局部纤维腺瘤病,怀疑存在微钙化,在乳腺X线检查中可确定多达10个微钙化。根据Le Gal III-rd类型,按照ACR 4的要求,在1平方厘米的面积上,在计算机X线断层扫描中确定硬结,至1平方厘米的10个微钙化,导管内乳头状瘤和不存在可疑的区域性乳突瘤。具有非侵袭性原位癌发展的中等风险,如果在临床上确定硬结或有血性分泌物的肿瘤形成,则在超声检查中发现局部纤维腺瘤病或微钙化形成,在乳腺钼靶检查中发现的范围大于根据Le Gal IV -V类型,acc 10钙化至1 cm2根据ACR 5并在计算机断层扫描上确定肿瘤的密度降低或局部纤维腺瘤病,多发性导管内乳头状瘤,10多个微钙化至1 cm2且不存在可疑的局部淋巴结转移灶,这是发展的主要风险原位无创性癌

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号